Associations Between High Levels of High-Density Lipoprotein Cholesterol and the Presence and Severity of Coronary Artery Disease in Patients Who Have Undergone Coronary Computed Tomography Angiography.
Coronary artery disease
Coronary computed tomography angiography
Gensini score
High-density lipoprotein cholesterol
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
06
10
2020
accepted:
17
10
2020
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
24
11
2020
Statut:
ppublish
Résumé
Although a recent study in a Japanese cohort indicated that extremely high-density lipoprotein cholesterol (HDL-C, ≥ 90 mg/dL) had an adverse effect on atherosclerotic cardiovascular disease mortality, we could not conclude that high levels of HDL-C were associated with the presence or severity of coronary artery disease (CAD). We enrolled 1,016 patients who were clinically suspected to have CAD and who underwent coronary computed tomography angiography (CCTA). The number of significantly stenosed coronary vessels (vessel disease (VD), ≥ 50% coronary stenosis is diagnosed as CAD) and the Gensini score were quantified using CCTA, and the lipid profile was measured. The patients were divided into four groups according to the HDL-C level: < 40 mg/dL (n = 115, low), 40 - 59 mg/dL (n = 530, normal), 60 - 89 mg/dL (n = 335, high) and ≥ 90 mg/dL (n = 36, very-high). The percentage (%) of CAD in the low, normal, high and very-high groups was 69%, 55%, 42% and 25%, respectively (P for trend < 0.01). The Gensini score in the low, normal, high and very-high groups was 20 ± 25, 12 ± 16, 8 ± 12 and 4 ± 6, respectively (P for trend < 0.01). The very-high group showed the lowest triglyceride (TG) levels among the four groups. There were no significant differences in the level of low-density lipoprotein cholesterol or % use of statin among the four groups. Finally, the presence of CAD was independently associated with a low level of HDL-C, in addition to age, male, high systolic blood pressure and hemoglobin A1c, but not TG, by a multivariate logistic regression analysis. High levels of HDL-C at the time of CCTA for screening were associated with a reduced presence and severity of CAD.
Sections du résumé
BACKGROUND
BACKGROUND
Although a recent study in a Japanese cohort indicated that extremely high-density lipoprotein cholesterol (HDL-C, ≥ 90 mg/dL) had an adverse effect on atherosclerotic cardiovascular disease mortality, we could not conclude that high levels of HDL-C were associated with the presence or severity of coronary artery disease (CAD).
METHODS
METHODS
We enrolled 1,016 patients who were clinically suspected to have CAD and who underwent coronary computed tomography angiography (CCTA). The number of significantly stenosed coronary vessels (vessel disease (VD), ≥ 50% coronary stenosis is diagnosed as CAD) and the Gensini score were quantified using CCTA, and the lipid profile was measured. The patients were divided into four groups according to the HDL-C level: < 40 mg/dL (n = 115, low), 40 - 59 mg/dL (n = 530, normal), 60 - 89 mg/dL (n = 335, high) and ≥ 90 mg/dL (n = 36, very-high).
RESULTS
RESULTS
The percentage (%) of CAD in the low, normal, high and very-high groups was 69%, 55%, 42% and 25%, respectively (P for trend < 0.01). The Gensini score in the low, normal, high and very-high groups was 20 ± 25, 12 ± 16, 8 ± 12 and 4 ± 6, respectively (P for trend < 0.01). The very-high group showed the lowest triglyceride (TG) levels among the four groups. There were no significant differences in the level of low-density lipoprotein cholesterol or % use of statin among the four groups. Finally, the presence of CAD was independently associated with a low level of HDL-C, in addition to age, male, high systolic blood pressure and hemoglobin A1c, but not TG, by a multivariate logistic regression analysis.
CONCLUSIONS
CONCLUSIONS
High levels of HDL-C at the time of CCTA for screening were associated with a reduced presence and severity of CAD.
Identifiants
pubmed: 33224375
doi: 10.14740/jocmr4367
pmc: PMC7665872
doi:
Types de publication
Journal Article
Langues
eng
Pagination
734-739Informations de copyright
Copyright 2020, Tashiro et al.
Déclaration de conflit d'intérêts
We have no conflict of interest.
Références
J Cardiol. 2015 Jun;65(6):487-93
pubmed: 25107604
Int Heart J. 2018 Jul 31;59(4):695-704
pubmed: 29877298
J Am Soc Nephrol. 2016 Feb;27(2):595-603
pubmed: 26319244
Expert Rev Cardiovasc Ther. 2012 Mar;10(3):353-61
pubmed: 22390807
J Am Coll Cardiol. 2016 Nov 8;68(19):2073-2083
pubmed: 27810046
Science. 2016 Mar 11;351(6278):1166-71
pubmed: 26965621
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Circ J. 2009 Jan;73(1):132-8
pubmed: 19039190
Pharmacol Ther. 2010 Jun;126(3):314-45
pubmed: 20153365
Heart Vessels. 2016 Aug;31(8):1257-65
pubmed: 26337618
Hypertens Res. 2019 Sep;42(9):1235-1481
pubmed: 31375757
Int J Cardiol. 2010 Aug 6;143(1):72-8
pubmed: 19237208
J Clin Hypertens (Greenwich). 2011 Mar;13(3):198-204
pubmed: 21366851
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
J Atheroscler Thromb. 2008 Apr;15(2):52-62
pubmed: 18385533
J Am Coll Cardiol. 2019 Feb 5;73(4):477-487
pubmed: 30704580
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Am J Cardiol. 2006 Feb 1;97(3):343-8
pubmed: 16442393
Am J Cardiol. 1983 Feb;51(3):606
pubmed: 6823874
Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):1961-1968
pubmed: 30354261
J Clin Lipidol. 2018 May - Jun;12(3):674-684.e5
pubmed: 29506864
J Atheroscler Thromb. 2010 Aug 31;17(8):870-8
pubmed: 20467190
Heart Vessels. 2017 Jan;32(1):30-38
pubmed: 27106918
J Atheroscler Thromb. 2016 Jul 1;23(7):800-9
pubmed: 26923252